<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315496</url>
  </required_header>
  <id_info>
    <org_study_id>GCIV_P3</org_study_id>
    <nct_id>NCT01315496</nct_id>
  </id_info>
  <brief_title>GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock</brief_title>
  <official_title>A Placebo-controlled, Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Administration of 'IV-Globulin S Inj.' in Adult Subjects With Community-Acquired Severe Sepsis or Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Symyoo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine whether the intravenous application of 'Ⅳ-Globulin S inj. (Human
      Immunoglobulin G)' can reduce mortality in patients with severe sepsis or septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Placebo-controlled, Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the
      Efficacy and Safety of Intravenous Administration of 'IV-Globulin S inj.(Human Immunoglobulin
      G)' as an Adjuvant Therapy in Adult Subjects with Community-Acquired Severe Sepsis or Septic
      Shock.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>28th day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>7th day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of SOFA subscores</measure>
    <time_frame>5 Times: D-1, D1, D3, D5, D7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test</measure>
    <time_frame>7th Day</time_frame>
    <description>sputum culture test, CBC, blood chemistry, blood coagulation test, CRP, ABGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU and general ward admission</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Imunoglobulin G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The enrolled patients will be randomized to receive supplementation of IVIG in ICU within 48 hours after hospital arrival admission for 3 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The enrolled patients will be randomized to receive supplementation of placebo (0.9% NaCl) in ICU within 48 hours after hospital arrival admission for 3 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunoglobulin G</intervention_name>
    <description>Immunoglobulin 1.5-2g/Kg/3days</description>
    <arm_group_label>Imunoglobulin G</arm_group_label>
    <arm_group_label>Placebo control</arm_group_label>
    <other_name>GCIV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with severe sepsis or septic shock, if all of the following criteria is
             satisfied.

               1. Age ≥ 18 years

               2. Proved or suspected infection in at least one site

          -  pneumonia

          -  urinary tract infection

          -  intra-abdominal infection

          -  primary bloodstream infection

          -  skin and soft tissue infection 3. Three or more of the following

          -  a core temperature ≥ 38° C or ≤ 36° C

          -  a heart rate ≥ 90 beats/min

          -  a respiratory rate ≥ 20 breaths/min or PaCO2 ≤ 32 mmHg or use of mechanical
             ventilation for an acute process

          -  a white blood cell count ≥ 12000/mm3 or ≤ 4000/ mm3 or immature neutrophils &gt; 10% 4.
             Acute organ failure in one or more of the following

          -  kidney

          -  respiratory system

          -  blood system

          -  metabolic system

          -  circulatory system 5. APACHE score ≥ 20 and ≤ 29 6. Patient can treatment with GCIV in
             ICU within at least 48 hours 7. Informed consent

        Exclusion Criteria:

          1. Pregnant or breast-feeding women

          2. a weight &gt; 100kg

          3. discharged from the hospital at least 14 days prior to new admission

          4. Transferred from another hospital staying more than 48 hours

          5. allergy or shock of IVIG

          6. Treated with IVIG within the 12 weeks immediately preceding enrolment in this study

          7. IgA deficiency

          8. Hypernatremia or hyperhydration

          9. Proved or suspected HIV or AIDS patients(CD4+ &lt;200mL)

         10. Current participation in any study within the last 4 weeks

         11. Do not resuscitate (DNR) status

         12. Patient's death is considered imminent due to coexisting disease

         13. physicians decision to exclude patients from this protocol

         14. Immunocompromised patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Ja Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyrongsang National University Hospital</name>
      <address>
        <city>Jinju-si, Gyeongsangnam-do,</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic of Korea Yeouido ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajuo University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>April 29, 2013</last_update_submitted>
  <last_update_submitted_qc>April 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Immunoglobulin G</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Septic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

